Member Info for DaffyPicker

But we have bought more than 60 million today in this range!!

14:45:31 0.545 10,000,000 54.50k Still didn't move MREX. 🙃

On August 12, 2025, Nicholas Gregory acquired 686,309 ordinary shares in FPP at 0.8725p per share, representing about 0.27% of the company’s share capital.

Let's get back into the 90s for a start.

"there is some uncertainty "

I love uncertainty. On some occasions it can make a share pop.!!

That's a shame. Can you buy some more at 0.89, I prefer that! 🤪

£263.50 k probably one of the Australian Pension Funds building a position early?!

What about 81 and 82? There should be some left unless there is background buying!

The 16.01s are sells, everything else is a buy. So, Yes!

Here are some late print buys from earlier. There may be more as well.

15:04:51 0.58 1,207,928 7,006 O

15:04:50 0.58 1,611,270 9,345 O

Once the 55s go, it may be 59 next.

Although they will probably tick it up to 56 or 57 first.

Mind you, never mind the money or the individual, Solvonis’s innovations offer society a chance to alleviate the heavy toll of addiction—restoring potential, easing suffering, and inspiring healthier communities. In this way, their work is not just medicine, but a beacon of hope, ....................................

USD 1.2 Billion will equate to about 57 pence per share. £0.57

Oops Sorry.

I valued it too low I think anyway. 🙃

Solvonis Therapeutics Plc Receives Takeover Offer of USD 1.2 Billion

Solvonis Therapeutics plc ("Solvonis" or the "Company"), a clinical-stage biopharmaceutical company focused on pioneering treatments for mental health and addiction disorders, announces that it has received a formal takeover offer valued at USD 1.2 billion.

I'm actually going to buy more next week.

I am going to need the PTSD and AUD solutions myself at this rate!! 🤪

I don't understand what's going on??!!??

SVN‑002 Phase 2b trial readiness, in alignment with Solvonis' clinical and regulatory development timelines is focused on the US AUD market, which remains significantly underserved and affects approximately 29 million individuals.

This has enormous value.

While the Company had previously anticipated selecting a single lead candidate at this stage, the positive performance of THREE candidates has delivered an optimal outcome - a strong, competitive shortlist with multiple best-in-class contenders. This outcome increases optionality, strengthens the dataset and enhances the probability of selecting a best-in-class candidate with strong commercial potential.

"Do you know IF any of those Co's are producing decent Profits?"

My lazy answer is no, I don't know. One AI answer is :-

Summary from QBT Consolidated Financials (2024):

Total revenue reported by QBT was zero for 2023 and 2024.

Administrative expenses and operating losses continue, reflecting investments in these technology and innovation startups.

Investment impairments recorded, signaling some valuation write-downs on these assets.

Cash position decreased due to operating losses and investment activities.

In essence, these investments are in early-stage or development phases with no notable revenue yet reported. They currently contribute as investment assets rather than income-generating entities in QBT’s consolidated financials, with some impairments reflecting revaluation.